Catabasis begins clinical trial on CAT-1004 drug candidte

Catabasis Pharmaceuticals has commenced the phase 1 clinical trial for its product candidate CAT-1004 to treat patients with type 2 diabetes.

CAT-1004, a chemical entity, is a conjugate of the essential omega-3 fatty acid docosahexaenoic acid (DHA) and salicylate.

The trial is intended to assess the safety, tolerability and pharmacokinetic profile of CAT-1004 in healthy adult subjects.

During the course of the study, nearly 60 subjects will receive a single dose of CAT-1004 or placebo via oral administration.

Preclinical studies have demonstrated that essential omega-3 fatty acid and salicylate exhibit anti-inflammatory activity.

Catabasis chief medical officer Joanne M. Donovan said CAT-1004 has the potential to improve insulin sensitivity and glucose homeostasis.